

REMARKS

In the Office Action, the Patent Office restricts the present application to one of the following inventions:

Group I: Claims 1-173, drawn to a method for treating neuropathic pain comprising administration of a composition comprising an opioid antagonist, classified in class 514, subclass 468, 765.

Group II: Claims 174-272, drawn to a composition for administration to a subject with neuropathic pain comprising an opioid agonist and an antagonist, classified in class 514, subclass 282, 468, 765.

In response, Applicants elect, without traverse, Group I.

The Patent Office also states that upon election of Group 1 or Group 2 that Applicant must further elect a single disclosed species of one opioid antagonist (the applicant selects naltrexone), one opioid agonist (the applicant selects morphine), one anticonvulsant (the applicant selects gabapentin), a non-narcotic analgesic (the applicant selects aspirin), a nonsteroidal anti-inflammatory (the applicant selects ibuprofen) a tricyclic antidepressant (the applicant selects desipramine), a glutamate receptor antagonist (the applicant selects ketamine), a anti-dynorphin agent (the applicant selects antibodies), a nicotinic receptor (the applicant selects A-85380), a local anesthetic (the applicant selects bupivacaine hydrochloride), a neuropathic pain (the applicant selects allodynia).

Accordingly, Applicants respectfully request that an examination on the merits of this case be conducted in due course.

Applicants reserve the right to file a divisional application(s), if necessary, to any non-elected claim subject matter.

The Commissioner is hereby authorized to charge deposit account 02-1818 for any fees which are due and owing.

Respectfully submitted,

BY



Robert Gould (43,642)

Cust. No. 29175

312-807-4244

Dated: March 5, 2007